世界のカルチノイド症候群管理市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Carcinoid Syndrome Management Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z1108
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、91ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、カルチノイド症候群管理のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、生物学的療法、肝動脈塞栓剤）、用途別市場規模（病院、クリニック、癌研究機関・治療センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・カルチノイド症候群管理の市場動向
・企業の競争状況、市場シェア
・カルチノイド症候群管理の種類別市場規模（化学療法、生物学的療法、肝動脈塞栓剤）
・カルチノイド症候群管理の用途別市場規模（病院、クリニック、癌研究機関・治療センター）
・カルチノイド症候群管理の北米市場規模2016-2027（アメリカ、カナダ）
・カルチノイド症候群管理のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・カルチノイド症候群管理のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・カルチノイド症候群管理の中南米市場規模2016-2027（メキシコ、ブラジル）
・カルチノイド症候群管理の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Novartis、Omega Laboratories、Teva Pharmaceutical、Mylan、Ipsen Biopharmaceuticals、Sirtex Medical、BTG International、Wockhardt、Sun Pharmaceutical）
・結論

Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor.
The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.

Market Analysis and Insights: Global Carcinoid Syndrome Management Market
The global Carcinoid Syndrome Management market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Carcinoid Syndrome Management market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Carcinoid Syndrome Management market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Carcinoid Syndrome Management market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Carcinoid Syndrome Management market.

Global Carcinoid Syndrome Management Scope and Market Size
Carcinoid Syndrome Management market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Carcinoid Syndrome Management market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chemotherapy
Biological Therapy
Hepatic Artery Embolization Agents

Segment by Application
Hospitals
Clinics
Cancer Institute and Treatment Centers

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis
Omega Laboratories
Teva Pharmaceutical
Mylan
Ipsen Biopharmaceuticals
Sirtex Medical
BTG International
Wockhardt
Sun Pharmaceutical

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Carcinoid Syndrome Management Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Biological Therapy
1.2.4 Hepatic Artery Embolization Agents
1.3 Market by Application
1.3.1 Global Carcinoid Syndrome Management Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Cancer Institute and Treatment Centers
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Carcinoid Syndrome Management Market Perspective (2016-2027)
2.2 Carcinoid Syndrome Management Growth Trends by Regions
2.2.1 Carcinoid Syndrome Management Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Carcinoid Syndrome Management Historic Market Share by Regions (2016-2021)
2.2.3 Carcinoid Syndrome Management Forecasted Market Size by Regions (2022-2027)
2.3 Carcinoid Syndrome Management Industry Dynamic
2.3.1 Carcinoid Syndrome Management Market Trends
2.3.2 Carcinoid Syndrome Management Market Drivers
2.3.3 Carcinoid Syndrome Management Market Challenges
2.3.4 Carcinoid Syndrome Management Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Carcinoid Syndrome Management Players by Revenue
3.1.1 Global Top Carcinoid Syndrome Management Players by Revenue (2016-2021)
3.1.2 Global Carcinoid Syndrome Management Revenue Market Share by Players (2016-2021)
3.2 Global Carcinoid Syndrome Management Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Carcinoid Syndrome Management Revenue
3.4 Global Carcinoid Syndrome Management Market Concentration Ratio
3.4.1 Global Carcinoid Syndrome Management Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Carcinoid Syndrome Management Revenue in 2020
3.5 Carcinoid Syndrome Management Key Players Head office and Area Served
3.6 Key Players Carcinoid Syndrome Management Product Solution and Service
3.7 Date of Enter into Carcinoid Syndrome Management Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Carcinoid Syndrome Management Breakdown Data by Type
4.1 Global Carcinoid Syndrome Management Historic Market Size by Type (2016-2021)
4.2 Global Carcinoid Syndrome Management Forecasted Market Size by Type (2022-2027)

5 Carcinoid Syndrome Management Breakdown Data by Application
5.1 Global Carcinoid Syndrome Management Historic Market Size by Application (2016-2021)
5.2 Global Carcinoid Syndrome Management Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Carcinoid Syndrome Management Market Size (2016-2027)
6.2 North America Carcinoid Syndrome Management Market Size by Type
6.2.1 North America Carcinoid Syndrome Management Market Size by Type (2016-2021)
6.2.2 North America Carcinoid Syndrome Management Market Size by Type (2022-2027)
6.2.3 North America Carcinoid Syndrome Management Market Size by Type (2016-2027)
6.3 North America Carcinoid Syndrome Management Market Size by Application
6.3.1 North America Carcinoid Syndrome Management Market Size by Application (2016-2021)
6.3.2 North America Carcinoid Syndrome Management Market Size by Application (2022-2027)
6.3.3 North America Carcinoid Syndrome Management Market Size by Application (2016-2027)
6.4 North America Carcinoid Syndrome Management Market Size by Country
6.4.1 North America Carcinoid Syndrome Management Market Size by Country (2016-2021)
6.4.2 North America Carcinoid Syndrome Management Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Carcinoid Syndrome Management Market Size (2016-2027)
7.2 Europe Carcinoid Syndrome Management Market Size by Type
7.2.1 Europe Carcinoid Syndrome Management Market Size by Type (2016-2021)
7.2.2 Europe Carcinoid Syndrome Management Market Size by Type (2022-2027)
7.2.3 Europe Carcinoid Syndrome Management Market Size by Type (2016-2027)
7.3 Europe Carcinoid Syndrome Management Market Size by Application
7.3.1 Europe Carcinoid Syndrome Management Market Size by Application (2016-2021)
7.3.2 Europe Carcinoid Syndrome Management Market Size by Application (2022-2027)
7.3.3 Europe Carcinoid Syndrome Management Market Size by Application (2016-2027)
7.4 Europe Carcinoid Syndrome Management Market Size by Country
7.4.1 Europe Carcinoid Syndrome Management Market Size by Country (2016-2021)
7.4.2 Europe Carcinoid Syndrome Management Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Carcinoid Syndrome Management Market Size (2016-2027)
8.2 Asia-Pacific Carcinoid Syndrome Management Market Size by Type
8.2.1 Asia-Pacific Carcinoid Syndrome Management Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Carcinoid Syndrome Management Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Carcinoid Syndrome Management Market Size by Type (2016-2027)
8.3 Asia-Pacific Carcinoid Syndrome Management Market Size by Application
8.3.1 Asia-Pacific Carcinoid Syndrome Management Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Carcinoid Syndrome Management Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Carcinoid Syndrome Management Market Size by Application (2016-2027)
8.4 Asia-Pacific Carcinoid Syndrome Management Market Size by Region
8.4.1 Asia-Pacific Carcinoid Syndrome Management Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Carcinoid Syndrome Management Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Carcinoid Syndrome Management Market Size (2016-2027)
9.2 Latin America Carcinoid Syndrome Management Market Size by Type
9.2.1 Latin America Carcinoid Syndrome Management Market Size by Type (2016-2021)
9.2.2 Latin America Carcinoid Syndrome Management Market Size by Type (2022-2027)
9.2.3 Latin America Carcinoid Syndrome Management Market Size by Type (2016-2027)
9.3 Latin America Carcinoid Syndrome Management Market Size by Application
9.3.1 Latin America Carcinoid Syndrome Management Market Size by Application (2016-2021)
9.3.2 Latin America Carcinoid Syndrome Management Market Size by Application (2022-2027)
9.3.3 Latin America Carcinoid Syndrome Management Market Size by Application (2016-2027)
9.4 Latin America Carcinoid Syndrome Management Market Size by Country
9.4.1 Latin America Carcinoid Syndrome Management Market Size by Country (2016-2021)
9.4.2 Latin America Carcinoid Syndrome Management Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Carcinoid Syndrome Management Market Size (2016-2027)
10.2 Middle East & Africa Carcinoid Syndrome Management Market Size by Type
10.2.1 Middle East & Africa Carcinoid Syndrome Management Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Carcinoid Syndrome Management Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Carcinoid Syndrome Management Market Size by Type (2016-2027)
10.3 Middle East & Africa Carcinoid Syndrome Management Market Size by Application
10.3.1 Middle East & Africa Carcinoid Syndrome Management Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Carcinoid Syndrome Management Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Carcinoid Syndrome Management Market Size by Application (2016-2027)
10.4 Middle East & Africa Carcinoid Syndrome Management Market Size by Country
10.4.1 Middle East & Africa Carcinoid Syndrome Management Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Carcinoid Syndrome Management Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Carcinoid Syndrome Management Introduction
11.1.4 Novartis Revenue in Carcinoid Syndrome Management Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Omega Laboratories
11.2.1 Omega Laboratories Company Details
11.2.2 Omega Laboratories Business Overview
11.2.3 Omega Laboratories Carcinoid Syndrome Management Introduction
11.2.4 Omega Laboratories Revenue in Carcinoid Syndrome Management Business (2016-2021)
11.2.5 Omega Laboratories Recent Development
11.3 Teva Pharmaceutical
11.3.1 Teva Pharmaceutical Company Details
11.3.2 Teva Pharmaceutical Business Overview
11.3.3 Teva Pharmaceutical Carcinoid Syndrome Management Introduction
11.3.4 Teva Pharmaceutical Revenue in Carcinoid Syndrome Management Business (2016-2021)
11.3.5 Teva Pharmaceutical Recent Development
11.4 Mylan
11.4.1 Mylan Company Details
11.4.2 Mylan Business Overview
11.4.3 Mylan Carcinoid Syndrome Management Introduction
11.4.4 Mylan Revenue in Carcinoid Syndrome Management Business (2016-2021)
11.4.5 Mylan Recent Development
11.5 Ipsen Biopharmaceuticals
11.5.1 Ipsen Biopharmaceuticals Company Details
11.5.2 Ipsen Biopharmaceuticals Business Overview
11.5.3 Ipsen Biopharmaceuticals Carcinoid Syndrome Management Introduction
11.5.4 Ipsen Biopharmaceuticals Revenue in Carcinoid Syndrome Management Business (2016-2021)
11.5.5 Ipsen Biopharmaceuticals Recent Development
11.6 Sirtex Medical
11.6.1 Sirtex Medical Company Details
11.6.2 Sirtex Medical Business Overview
11.6.3 Sirtex Medical Carcinoid Syndrome Management Introduction
11.6.4 Sirtex Medical Revenue in Carcinoid Syndrome Management Business (2016-2021)
11.6.5 Sirtex Medical Recent Development
11.7 BTG International
11.7.1 BTG International Company Details
11.7.2 BTG International Business Overview
11.7.3 BTG International Carcinoid Syndrome Management Introduction
11.7.4 BTG International Revenue in Carcinoid Syndrome Management Business (2016-2021)
11.7.5 BTG International Recent Development
11.8 Wockhardt
11.8.1 Wockhardt Company Details
11.8.2 Wockhardt Business Overview
11.8.3 Wockhardt Carcinoid Syndrome Management Introduction
11.8.4 Wockhardt Revenue in Carcinoid Syndrome Management Business (2016-2021)
11.8.5 Wockhardt Recent Development
11.9 Sun Pharmaceutical
11.9.1 Sun Pharmaceutical Company Details
11.9.2 Sun Pharmaceutical Business Overview
11.9.3 Sun Pharmaceutical Carcinoid Syndrome Management Introduction
11.9.4 Sun Pharmaceutical Revenue in Carcinoid Syndrome Management Business (2016-2021)
11.9.5 Sun Pharmaceutical Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Carcinoid Syndrome Management Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Biological Therapy
Table 4. Key Players of Hepatic Artery Embolization Agents
Table 5. Global Carcinoid Syndrome Management Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Carcinoid Syndrome Management Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Carcinoid Syndrome Management Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Carcinoid Syndrome Management Market Share by Regions (2016-2021)
Table 9. Global Carcinoid Syndrome Management Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Carcinoid Syndrome Management Market Share by Regions (2022-2027)
Table 11. Carcinoid Syndrome Management Market Trends
Table 12. Carcinoid Syndrome Management Market Drivers
Table 13. Carcinoid Syndrome Management Market Challenges
Table 14. Carcinoid Syndrome Management Market Restraints
Table 15. Global Carcinoid Syndrome Management Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Carcinoid Syndrome Management Market Share by Players (2016-2021)
Table 17. Global Top Carcinoid Syndrome Management Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Carcinoid Syndrome Management as of 2020)
Table 18. Ranking of Global Top Carcinoid Syndrome Management Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Carcinoid Syndrome Management Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Carcinoid Syndrome Management Product Solution and Service
Table 22. Date of Enter into Carcinoid Syndrome Management Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Carcinoid Syndrome Management Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Carcinoid Syndrome Management Revenue Market Share by Type (2016-2021)
Table 26. Global Carcinoid Syndrome Management Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Carcinoid Syndrome Management Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Carcinoid Syndrome Management Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Carcinoid Syndrome Management Revenue Market Share by Application (2016-2021)
Table 30. Global Carcinoid Syndrome Management Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Carcinoid Syndrome Management Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Carcinoid Syndrome Management Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Carcinoid Syndrome Management Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Carcinoid Syndrome Management Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Carcinoid Syndrome Management Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Carcinoid Syndrome Management Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Carcinoid Syndrome Management Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Carcinoid Syndrome Management Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Carcinoid Syndrome Management Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Carcinoid Syndrome Management Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Carcinoid Syndrome Management Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Carcinoid Syndrome Management Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Carcinoid Syndrome Management Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Carcinoid Syndrome Management Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Carcinoid Syndrome Management Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Carcinoid Syndrome Management Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Carcinoid Syndrome Management Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Carcinoid Syndrome Management Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Carcinoid Syndrome Management Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Carcinoid Syndrome Management Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Carcinoid Syndrome Management Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Carcinoid Syndrome Management Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Carcinoid Syndrome Management Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Carcinoid Syndrome Management Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Carcinoid Syndrome Management Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Carcinoid Syndrome Management Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Carcinoid Syndrome Management Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Carcinoid Syndrome Management Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Carcinoid Syndrome Management Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Carcinoid Syndrome Management Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Carcinoid Syndrome Management Market Size by Country (2022-2027) & (US$ Million)
Table 62. Novartis Company Details
Table 63. Novartis Business Overview
Table 64. Novartis Carcinoid Syndrome Management Product
Table 65. Novartis Revenue in Carcinoid Syndrome Management Business (2016-2021) & (US$ Million)
Table 66. Novartis Recent Development
Table 67. Omega Laboratories Company Details
Table 68. Omega Laboratories Business Overview
Table 69. Omega Laboratories Carcinoid Syndrome Management Product
Table 70. Omega Laboratories Revenue in Carcinoid Syndrome Management Business (2016-2021) & (US$ Million)
Table 71. Omega Laboratories Recent Development
Table 72. Teva Pharmaceutical Company Details
Table 73. Teva Pharmaceutical Business Overview
Table 74. Teva Pharmaceutical Carcinoid Syndrome Management Product
Table 75. Teva Pharmaceutical Revenue in Carcinoid Syndrome Management Business (2016-2021) & (US$ Million)
Table 76. Teva Pharmaceutical Recent Development
Table 77. Mylan Company Details
Table 78. Mylan Business Overview
Table 79. Mylan Carcinoid Syndrome Management Product
Table 80. Mylan Revenue in Carcinoid Syndrome Management Business (2016-2021) & (US$ Million)
Table 81. Mylan Recent Development
Table 82. Ipsen Biopharmaceuticals Company Details
Table 83. Ipsen Biopharmaceuticals Business Overview
Table 84. Ipsen Biopharmaceuticals Carcinoid Syndrome Management Product
Table 85. Ipsen Biopharmaceuticals Revenue in Carcinoid Syndrome Management Business (2016-2021) & (US$ Million)
Table 86. Ipsen Biopharmaceuticals Recent Development
Table 87. Sirtex Medical Company Details
Table 88. Sirtex Medical Business Overview
Table 89. Sirtex Medical Carcinoid Syndrome Management Product
Table 90. Sirtex Medical Revenue in Carcinoid Syndrome Management Business (2016-2021) & (US$ Million)
Table 91. Sirtex Medical Recent Development
Table 92. BTG International Company Details
Table 93. BTG International Business Overview
Table 94. BTG International Carcinoid Syndrome Management Product
Table 95. BTG International Revenue in Carcinoid Syndrome Management Business (2016-2021) & (US$ Million)
Table 96. BTG International Recent Development
Table 97. Wockhardt Company Details
Table 98. Wockhardt Business Overview
Table 99. Wockhardt Revenue in Carcinoid Syndrome Management Business (2016-2021) & (US$ Million)
Table 100. Wockhardt Recent Development
Table 101. Sun Pharmaceutical Company Details
Table 102. Sun Pharmaceutical Business Overview
Table 103. Sun Pharmaceutical Carcinoid Syndrome Management Product
Table 104. Sun Pharmaceutical Revenue in Carcinoid Syndrome Management Business (2016-2021) & (US$ Million)
Table 105. Sun Pharmaceutical Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Carcinoid Syndrome Management Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Features
Figure 3. Biological Therapy Features
Figure 4. Hepatic Artery Embolization Agents Features
Figure 5. Global Carcinoid Syndrome Management Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Cancer Institute and Treatment Centers Case Studies
Figure 9. Carcinoid Syndrome Management Report Years Considered
Figure 10. Global Carcinoid Syndrome Management Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Carcinoid Syndrome Management Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Carcinoid Syndrome Management Market Share by Regions: 2020 VS 2027
Figure 13. Global Carcinoid Syndrome Management Market Share by Regions (2022-2027)
Figure 14. Global Carcinoid Syndrome Management Market Share by Players in 2020
Figure 15. Global Top Carcinoid Syndrome Management Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Carcinoid Syndrome Management as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Carcinoid Syndrome Management Revenue in 2020
Figure 17. Global Carcinoid Syndrome Management Revenue Market Share by Type (2016-2021)
Figure 18. Global Carcinoid Syndrome Management Revenue Market Share by Type (2022-2027)
Figure 19. North America Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Carcinoid Syndrome Management Market Share by Type (2016-2027)
Figure 21. North America Carcinoid Syndrome Management Market Share by Application (2016-2027)
Figure 22. North America Carcinoid Syndrome Management Market Share by Country (2016-2027)
Figure 23. United States Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Carcinoid Syndrome Management Market Share by Type (2016-2027)
Figure 27. Europe Carcinoid Syndrome Management Market Share by Application (2016-2027)
Figure 28. Europe Carcinoid Syndrome Management Market Share by Country (2016-2027)
Figure 29. Germany Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Carcinoid Syndrome Management Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Carcinoid Syndrome Management Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Carcinoid Syndrome Management Market Share by Region (2016-2027)
Figure 39. China Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Carcinoid Syndrome Management Market Share by Type (2016-2027)
Figure 47. Latin America Carcinoid Syndrome Management Market Share by Application (2016-2027)
Figure 48. Latin America Carcinoid Syndrome Management Market Share by Country (2016-2027)
Figure 49. Mexico Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Carcinoid Syndrome Management Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Carcinoid Syndrome Management Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Carcinoid Syndrome Management Market Share by Country (2016-2027)
Figure 55. Turkey Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Carcinoid Syndrome Management Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Novartis Revenue Growth Rate in Carcinoid Syndrome Management Business (2016-2021)
Figure 59. Omega Laboratories Revenue Growth Rate in Carcinoid Syndrome Management Business (2016-2021)
Figure 60. Teva Pharmaceutical Revenue Growth Rate in Carcinoid Syndrome Management Business (2016-2021)
Figure 61. Mylan Revenue Growth Rate in Carcinoid Syndrome Management Business (2016-2021)
Figure 62. Ipsen Biopharmaceuticals Revenue Growth Rate in Carcinoid Syndrome Management Business (2016-2021)
Figure 63. Sirtex Medical Revenue Growth Rate in Carcinoid Syndrome Management Business (2016-2021)
Figure 64. BTG International Revenue Growth Rate in Carcinoid Syndrome Management Business (2016-2021)
Figure 65. Wockhardt Revenue Growth Rate in Carcinoid Syndrome Management Business (2016-2021)
Figure 66. Sun Pharmaceutical Revenue Growth Rate in Carcinoid Syndrome Management Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

以下、関連資料のご紹介

世界のカルチノイド症候群下痢治療市場規模・現状・予測（2021年-2027年）

Global Carcinoid Syndrome Diarrhea Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1107 2021年4月 95Pages
QYResearch社発行の本調査資料では、カルチノイド症候群下痢治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、ソマトスタチンアナログ（SSA）療法、経口療法）、用途別市場規模（病院、クリニック、がん研究所）、主要地域別市場規模...

世界のゾリンジャー-エリソン症候群検査市場規模・現状・予測（2021年-2027年）

Global Zollinger - Ellison Syndrome Testing Market Size, Status and Forecast 2021-2027
QYR2104Z6110 2021年4月 92Pages
QYResearch社発行の本調査資料では、ゾリンジャー-エリソン症候群検査のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（合成豚セクレチン、合成人間セクレチン）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッ...

世界の周期的発熱症候群市場規模・現状・予測（2021年-2027年）

Global Periodic Fever Syndrome Market Size, Status and Forecast 2021-2027
QYR2104Z4515 2021年4月 99Pages
QYResearch社発行の本調査資料では、周期的発熱症候群のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（高IgD症候群、家族性地中海熱症候群、TNF受容体関連周期症候群、クリオピリン関連周期症候群、その他）、用途別市場規模（病院、ドラッグス...

世界の脆弱X症候群遺伝子検査市場規模・現状・予測（2021年-2027年）

Global Fragile X Syndrome Genetic Testing Market Size, Status and Forecast 2021-2027
QYR2104Z2456 2021年4月 97Pages
QYResearch社発行の本調査資料では、脆弱X症候群遺伝子検査のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（遺伝子スクリーニング、生殖遺伝子検査、診断検査、遺伝子保因者検査、症状前検査）、用途別市場規模（病院、クリニック、診断センター）、...

世界のチャーグストラウス症候群市場規模・現状・予測（2021年-2027年）

Global Churg Strauss Syndrome Market Size, Status and Forecast 2021-2027
QYR2104Z1332 2021年4月 99Pages
QYResearch社発行の本調査資料では、チャーグストラウス症候群のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（生物製剤、免疫グロブリン、ワクチン、ステロイド、その他）、用途別市場規模（研究所、病院、クリニック、その他）、主要地域別市場規模...

世界の腫瘍崩壊症候群市場規模・現状・予測（2021年-2027年）

Global Tumor Lysis Syndrome Market Size, Status and Forecast 2021-2027
QYR2104Z5758 2021年4月 92Pages
QYResearch社発行の本調査資料では、腫瘍崩壊症候群のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アロプリノール、フェブキソスタット、ラスブリカーゼ、その他）、用途別市場規模（病院薬局、小売薬局、その他）、主要地域別市場規模（北米、アメ...

世界のドラベ症候群治療市場規模・現状・予測（2021年-2027年）

Global Dravet Syndrome Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1961 2021年4月 92Pages
QYResearch社発行の本調査資料では、ドラベ症候群治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（第一世代薬品（FGD）、第二世代薬品（SGD）、第三世代薬品（TGD））、用途別市場規模（病院薬局、小売薬局、Eコマース、その他）、主要...

世界のバーター症候群治療薬市場規模・現状・予測（2021年-2027年）

Global Bartter Syndrome Drugs Market Size, Status and Forecast 2021-2027
QYR2104Z0704 2021年4月 93Pages
QYResearch社発行の本調査資料では、バーター症候群治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（NSAID（非ステロイド性抗炎症薬）、RAAS阻害剤、アルドステロン拮抗薬、アンジオテンシンII受容体拮抗薬、アンジオテンシン変換酵...

世界の吸収不良症候群市場規模・現状・予測（2021年-2027年）

Global Malabsorption Syndrome Market Size, Status and Forecast 2021-2027
QYR2104Z3532 2021年4月 90Pages
QYResearch社発行の本調査資料では、吸収不良症候群のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（栄養補助食品、プロテアーゼ・リパーゼサプリメント、抗生物質、止瀉薬、抗炎症薬、その他）、用途別市場規模（製薬会社、病院、栄養クリニック、学...

世界のバーター症候群治療市場規模・現状・予測（2021年-2027年）

Global Bartter Syndrome Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0705 2021年4月 93Pages
QYResearch社発行の本調査資料では、バーター症候群治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（NSAID（非ステロイド性抗炎症薬）、RAAS阻害剤、アルドステロン拮抗薬、アンジオテンシンII受容体拮抗薬、アンジオテンシン変換酵素...

世界のカルチノイド症候群下痢治療市場規模・現状・予測（2021年-2027年） Carcinoid syndrome is a group of symptoms that can occur in patients suffering from carcinoid tumors which also called as metastatic neuroendocrine tumors. Carcinoid tumors are rare and these are slow growing tumors. Most of the tumors occur in gastrointestinal tract. According to FDA, carcinoid syn…
世界の化学療法薬誘発性肢端紅斑（手足症候群）治療市場規模・現状・予測（2021年-2027年） Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear afte…
世界の腫瘍随伴症候群治療市場規模・現状・予測（2021年-2027年） A paraneoplastic syndrome is a rare group of disorder that is triggered by an abnormal immune system response caused by the neoplasm. This syndrome mostly occurs when cancer-fighting antibodies mistakenly attack normal cells in the nervous system. The prevalence of this disorder can be typically see…
世界のスタージーウェーバー症候群（SWS）治療市場規模・現状・予測（2021年-2027年） Sturge-Weber syndrome or Sturge-Weber-Krabbe disease, sometimes referred to as encephalotrigeminal angiomatosis, is a rare congenital neurological and skin disorder. It is one of the phakomatoses and is often associated with port-wine stains of the face, glaucoma, seizures, mental retardation, and i…
世界の多嚢胞性卵巣症候群治療市場規模・現状・予測（2021年-2027年） Polycystic ovary syndrome is a set of symptoms due to elevated androgens in females. Signs and symptoms of polycystic ovary syndrome nclude irregular or no menstrual periods, heavy periods, excess body and facial hair, acne, pelvic pain, difficulty getting pregnant and patches of thick, darker, velv…